JPWO2020072601A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072601A5 JPWO2020072601A5 JP2021518610A JP2021518610A JPWO2020072601A5 JP WO2020072601 A5 JPWO2020072601 A5 JP WO2020072601A5 JP 2021518610 A JP2021518610 A JP 2021518610A JP 2021518610 A JP2021518610 A JP 2021518610A JP WO2020072601 A5 JPWO2020072601 A5 JP WO2020072601A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutical composition
- poloxamer
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 143
- 238000000034 method Methods 0.000 claims description 70
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 53
- 229920001983 poloxamer Polymers 0.000 claims description 46
- 229960000502 poloxamer Drugs 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 19
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 17
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 14
- 229960000604 valproic acid Drugs 0.000 claims description 14
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 8
- 150000001299 aldehydes Chemical class 0.000 claims description 7
- 229920001992 poloxamer 407 Polymers 0.000 claims description 7
- 229940044476 poloxamer 407 Drugs 0.000 claims description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 6
- 206010011891 Deafness neurosensory Diseases 0.000 claims description 5
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims description 5
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims description 5
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims description 5
- 229940084026 sodium valproate Drugs 0.000 claims description 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 5
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000012535 impurity Substances 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229920000428 triblock copolymer Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 3
- 229940125703 otic agent Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 1
- 108060006662 GSK3 Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739933P | 2018-10-02 | 2018-10-02 | |
| US62/739,933 | 2018-10-02 | ||
| PCT/US2019/054235 WO2020072601A1 (en) | 2018-10-02 | 2019-10-02 | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504265A JP2022504265A (ja) | 2022-01-13 |
| JP2022504265A5 JP2022504265A5 (https=) | 2022-10-07 |
| JPWO2020072601A5 true JPWO2020072601A5 (https=) | 2022-10-07 |
Family
ID=68296763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518610A Withdrawn JP2022504265A (ja) | 2018-10-02 | 2019-10-02 | 耳治療薬に関する医薬組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220192984A1 (https=) |
| EP (1) | EP3860562A1 (https=) |
| JP (1) | JP2022504265A (https=) |
| KR (1) | KR20210084484A (https=) |
| CN (1) | CN113164381A (https=) |
| BR (1) | BR112021006092A2 (https=) |
| CA (1) | CA3114113A1 (https=) |
| MX (1) | MX2021003773A (https=) |
| TW (1) | TW202034900A (https=) |
| WO (2) | WO2020072602A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| CN113195707A (zh) * | 2018-08-17 | 2021-07-30 | 频率治疗公司 | 用于通过上调jag-1来生成毛细胞的组合物和方法 |
| KR20220007050A (ko) * | 2019-04-08 | 2022-01-18 | 프리퀀시 테라퓨틱스, 인크. | 난청을 치료하기 위한 chir99021과 발프로산의 조합 |
| CN114085803B (zh) * | 2020-08-24 | 2024-04-26 | 北京大学 | 建立具有再生特性的类器官培养体系 |
| CA3195622A1 (en) * | 2020-10-14 | 2022-04-21 | Ear Science Institute Australia Incorporated | Methods for generating inner ear hair cells |
| WO2022192079A1 (en) * | 2021-03-08 | 2022-09-15 | The Regents Of The University Of California | Compounds for protection of noise-induced hearing-loss |
| EP4629989A2 (en) * | 2022-12-07 | 2025-10-15 | Freedom Biosciences, Inc. | Treatment or prevention of depressive disorders through combination therapy |
| CN120053473B (zh) * | 2025-04-25 | 2025-07-18 | 山东大学 | 赖氨酸甲基转移酶dot1l抑制剂在制备治疗肝脏缺血再灌注损伤药物中的应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US447475A (en) | 1891-03-03 | pomerof | ||
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US5346703A (en) | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| WO2000007603A2 (en) | 1998-08-04 | 2000-02-17 | Madash Llp | End modified thermal responsive hydrogels |
| US6761824B2 (en) | 2000-08-17 | 2004-07-13 | Reeve Lorraine E | Process for the fractionation of polymers |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| EP2732819B1 (en) | 2008-02-07 | 2019-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
| EP2854809B1 (en) | 2012-06-01 | 2017-12-06 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI) | Inhibitors of the notch signalling pathway and secretion for use in medicine |
| CA2883896C (en) | 2012-09-07 | 2023-03-07 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
| WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
| TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥 |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| WO2014047391A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
| EP2897960B1 (en) | 2012-09-21 | 2016-08-03 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
| EP2897947B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
| WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
| EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
| US9572815B2 (en) | 2013-03-15 | 2017-02-21 | St. Jude Children's Research Hospital | Methods and compositions of p27KIP1 transcriptional modulators |
| CN103169649A (zh) * | 2013-04-11 | 2013-06-26 | 中国人民解放军总医院 | 温度和离子双重敏感型原位凝胶鼻腔给药系统 |
| WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
| WO2016037016A1 (en) * | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| CN107075471A (zh) | 2014-10-08 | 2017-08-18 | 新加坡科技研究局 | 将干细胞分化为肝细胞谱系的方法 |
| TWI625332B (zh) | 2015-07-07 | 2018-06-01 | 美國禮來大藥廠 | 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物 |
| KR102723605B1 (ko) | 2015-12-22 | 2024-10-29 | 바스프 에스이 | 폴리에테르 블록 공중합체의 정제 방법 |
| US10201540B2 (en) * | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) * | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| JP7012715B2 (ja) | 2016-06-27 | 2022-01-28 | エフ．ホフマン－ラ ロシュ アーゲー | γ－セクレターゼモジュレーターとしてのトリアゾロピリジン |
| EP3481829B1 (en) | 2016-07-08 | 2021-04-07 | H. Hoffnabb-La Roche Ag | Fused pyrimidine derivatives |
| EP3484884B1 (en) | 2016-07-14 | 2021-01-27 | Hoffmann-La Roche AG | Fused pyrimidine derivatives |
| AR109829A1 (es) | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| EP3523304B1 (en) | 2016-10-04 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bicyclic heteroaryl derivatives |
| TWI757360B (zh) | 2016-11-08 | 2022-03-11 | 瑞士商赫孚孟拉羅股份公司 | 苯氧基三唑 |
| MX390370B (es) | 2016-12-16 | 2025-03-20 | Pipeline Therapeutics Inc | Metodos para tratar la sinaptopatia coclear |
| CA3047730A1 (en) | 2016-12-20 | 2018-06-28 | Oligomerix, Inc. | Quinazolinones that inhibit the formation of tau oligomers and their method of use |
| CA3047729A1 (en) | 2016-12-20 | 2018-06-28 | Oligomerix, Inc. | Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use |
| US10383881B2 (en) | 2016-12-30 | 2019-08-20 | Frequency Therapeutics, Inc. | 1,5-dihydro-2H-pyrrol-2-one compounds and methods of using same |
| US11066419B2 (en) | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
| WO2018172997A1 (en) | 2017-03-24 | 2018-09-27 | Novartis Ag | Isoxazole carboxamide compounds and uses thereof |
-
2019
- 2019-10-02 TW TW108135698A patent/TW202034900A/zh unknown
- 2019-10-02 MX MX2021003773A patent/MX2021003773A/es unknown
- 2019-10-02 US US17/282,069 patent/US20220192984A1/en not_active Abandoned
- 2019-10-02 CN CN201980079535.3A patent/CN113164381A/zh active Pending
- 2019-10-02 JP JP2021518610A patent/JP2022504265A/ja not_active Withdrawn
- 2019-10-02 WO PCT/US2019/054236 patent/WO2020072602A1/en not_active Ceased
- 2019-10-02 CA CA3114113A patent/CA3114113A1/en active Pending
- 2019-10-02 EP EP19791035.9A patent/EP3860562A1/en not_active Withdrawn
- 2019-10-02 KR KR1020217013189A patent/KR20210084484A/ko not_active Withdrawn
- 2019-10-02 BR BR112021006092-8A patent/BR112021006092A2/pt not_active Application Discontinuation
- 2019-10-02 WO PCT/US2019/054235 patent/WO2020072601A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6870867B2 (ja) | メロキシカムを含有する医薬組成物 | |
| CN100563655C (zh) | 治疗牛和猪感染的组合物及其用途 | |
| KR102233537B1 (ko) | 항균성 폴리아미드 조성물 및 유방염 치료 | |
| CN1195504C (zh) | 含非甾族消炎止痛剂的外用药物制剂 | |
| JPWO2020072601A5 (https=) | ||
| US20210220428A1 (en) | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells | |
| CN101897687B (zh) | 丙戊酸钠治疗肝脏炎症相关疾病的新用途 | |
| JP3140409B2 (ja) | 安定なプロスタグランジンｅ１−含有注射剤組成物 | |
| KR101810156B1 (ko) | 폴리에틸렌 글리콜 및 플라보노이드 나노복합체를 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물 | |
| TWI510243B (zh) | 用於治療膀胱癌的組成物及方法 | |
| CN116942618B (zh) | 一种适用于耳鼓给药的地塞米松磷酸钠冻干组合物及其制备方法 | |
| Pan | Ultrasound guided intralesional bleomycin therapy for cystic lymphangioma in childhood | |
| JP4617303B2 (ja) | フルピルチンの注射用医薬形 | |
| CN109820945B (zh) | 促进皮肤创伤愈合及毛发生长的组合药物及其制备方法 | |
| JP2007517847A (ja) | セルロース誘導体で架橋された柑橘類複合糖質のゲル組成物 | |
| CN113811309B (zh) | 用于治疗病毒感染的聚合物制剂及制备方法和用途 | |
| KR20240125025A (ko) | 청각 질환을 치료하기 위한 4-페닐-테트라히드로피리딘 유도체 | |
| CN108883160A (zh) | 因子xa解毒剂的冻干制剂 | |
| RU2423130C2 (ru) | Композиция, содержащая эпопростенол, и способ ее получения | |
| CN115887354A (zh) | 一种消化道粘膜损伤快速修复新材料及制备方法 | |
| CN103845463B (zh) | 治疗马骨关节炎性肿胀的中药透皮剂及其制备方法 | |
| WO2021157619A1 (ja) | 膵液瘻の予防または治療剤 | |
| RU2589840C1 (ru) | Гидрофильный гель для раневого покрытия | |
| CN102144979B (zh) | 用于治疗肿瘤的左旋棉酚或其醋酸盐的注射用冻干粉制剂 | |
| CN114025746A (zh) | 抗血栓形成剂的可注射聚合物纳米颗粒组合物及其方法 |